A robust CD8(+) T cell-related classifier for predicting the prognosis and efficacy of immunotherapy in stage III lung adenocarcinoma

Patients with stage III lung adenocarcinoma (LUAD) have significant survival heterogeneity, meanwhile, CD8(+) T cell has a remarkable function in immunotherapy. Therefore, developing novel biomarkers based on CD8(+) T cell can help evaluate the prognosis and guide the strategy of immunotherapy for p...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Jinteng, Xu, Longwen, Zhang, Shirong, Geng, Luying, Zhang, Tian, Yu, Yang, Yuan, Rui, He, Yusheng, Nan, Zhuhui, Lin, Min, Guo, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471021/
https://www.ncbi.nlm.nih.gov/pubmed/36119068
http://dx.doi.org/10.3389/fimmu.2022.993187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471021/
https://www.ncbi.nlm.nih.gov/pubmed/36119068
http://dx.doi.org/10.3389/fimmu.2022.993187

Ejemplares similares